BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25139406)

  • 1. Therapeutic decision making in patients with newly diagnosed low grade glioma.
    Tandon A; Schiff D
    Curr Treat Options Oncol; 2014 Dec; 15(4):529-38. PubMed ID: 25139406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
    Nahed BV; Redjal N; Brat DJ; Chi AS; Oh K; Batchelor TT; Ryken TC; Kalkanis SN; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):609-30. PubMed ID: 26530264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benign Glioma.
    Wu PB; Filley AC; Miller ML; Bruce JN
    Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
    Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
    Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-grade glioma.
    Kumthekar P; Raizer J; Singh S
    Cancer Treat Res; 2015; 163():75-87. PubMed ID: 25468226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade gliomas.
    Stieber VW
    Curr Treat Options Oncol; 2001 Dec; 2(6):495-506. PubMed ID: 12057095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of low-grade glioma.
    Pouratian N; Schiff D
    Curr Neurol Neurosci Rep; 2010 May; 10(3):224-31. PubMed ID: 20425038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
    Fouke SJ; Benzinger T; Gibson D; Ryken TC; Kalkanis SN; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):457-79. PubMed ID: 26530262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary management of adult low grade gliomas.
    Mariş D; Nica D; Mohan D; Moisa H; Ciurea AV
    Chirurgia (Bucur); 2014; 109(5):590-9. PubMed ID: 25375042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of low-grade gliomas.
    Hottinger AF; Hegi ME; Baumert BG
    Curr Opin Neurol; 2016 Dec; 29(6):782-788. PubMed ID: 27676279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
    Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
    Koo T; Lim DH; Seol HJ; Park CK; Kim IH; Chang JH; Lee J; Jung S; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
    J Neurooncol; 2018 Jul; 138(3):667-677. PubMed ID: 29572674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical management of incidentally discovered diffusely infiltrating low-grade glioma.
    Opoku-Darko M; Lang ST; Artindale J; Cairncross JG; Sevick RJ; Kelly JJP
    J Neurosurg; 2018 Jul; 129(1):19-26. PubMed ID: 28984519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
    Wirsching HG; Weller M
    Curr Treat Options Oncol; 2016 Oct; 17(10):51. PubMed ID: 27501915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.